A share price of Zentalis Pharmaceuticals Inc [ZNTL] is currently trading at $3.49, down -6.68%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ZNTL shares have gain 154.74% over the last week, with a monthly amount glided 145.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] stock has seen the most recent analyst activity on August 12, 2024, when Wedbush upgraded its rating to a Neutral but kept the price target unchanged to $4 for it. Previously, UBS downgraded its rating to Neutral on June 20, 2024, and dropped its price target to $5. On June 18, 2024, downgrade downgraded it’s rating to Equal Weight. Wedbush downgraded its rating to an Underperform and decreased its price target to $4 on June 18, 2024. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $8 on June 18, 2024. Jefferies downgraded its rating to Hold for this stock on June 18, 2024, and downed its price target to $6. In a note dated November 08, 2023, Wedbush downgraded a Neutral rating on this stock and revised its target price from $38 to $12.
Zentalis Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $1.01 and $3.81. Currently, Wall Street analysts expect the stock to reach $2 within the next 12 months. Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] shares were valued at $3.49 at the most recent close of the market. An investor can expect a potential drop of -42.69% based on the average ZNTL price forecast.
Analyzing the ZNTL fundamentals
Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -6.81%, Pretax Profit Margin comes in at -6.07%, and Net Profit Margin reading is -6.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.52 and Total Capital is -0.59. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] is 7.76. Further, the Quick Ratio stands at 7.76, while the Cash Ratio is 0.96. Considering the valuation of this stock, the price to sales ratio is 9.39, the price to book ratio is 1.00.
Transactions by insiders
Recent insider trading involved WALTERS GROUP, 10% Owner, that happened on Dec 31 ’25 when 6.46 million shares were purchased. 10% Owner, Matrix Capital Management Comp completed a deal on Dec 15 ’25 to sell 7.5 million shares. Meanwhile, Director Myers Scott Dunseth bought 21000.0 shares on Apr 30 ’25.
